Sanofi licensed worldwide rights to MannKind's Afrezza inhaled insulin for $150M upfront plus up to $775M in regulatory and sales milestones with profit share. Strategically high-profile but ultimately unsuccessful—Sanofi terminated the alliance in January 2016 amid weak launch performance.
Key facts
AnnouncedAug 11, 2014
ClosedSep 23, 2014
Deal value$925M
Deal typeLicensing/Option
Therapeutic areaType 1 and type 2 diabetes mellitus
IndicationsType 1 and type 2 diabetes mellitus
Key assetsAfrezza (insulin human inhalation powder) plus Technosphere device
MechanismInhaled prandial insulin via Technosphere dry-powder formulation